AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Acute Lymphoblastic Leukemia, Adult B-Cell

Whole Genome Sequencing (ChromoSeqยฎ) for Acute Lymphoblastic Leukemia (ALL) Patients NCT07313592n/a1 site๐Ÿ“ St Louis Washington University School of Medicine A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia NCT07400029Phase 29 sites๐Ÿ“ Duarte๐Ÿ“ Stanford๐Ÿ“ Basking Ridge Memorial Sloan Kettering Cancer Center ยท Tests: Obecabtagene Autoleucel Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081NA1 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: Senl_B19 autologous CAR-T (S1904) treatment A Phase I Dose Finding Study of MB-CART2219.1 NCT07108868Phase 12 sites๐Ÿ“ Tรผbingen๐Ÿ“ Tรผbingen University Hospital Tuebingen ยท Tests: CAR-T cells targeting CD19 and CD22 Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: biologic sample preservation procedure, cytology specimen collection procedure BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL NCT07008885Phase 1, Phase 22 sites๐Ÿ“ Beijing๐Ÿ“ Beijing Chinese PLA General Hospital ยท Tests: CAR19TIF cells, Fludarabine, Cyclophosphamide Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL NCT06481228NA1 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: CAR-T cells, Venetoclax, Olverembatinib Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dualโ€ฆ TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL NCT06481735Phase 1, Phase 26 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Beijing Chinese PLA General Hospital ยท Tests: TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell, Fludarabine, Cyclophosphamide Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies NCT05658640Phase 1, Phase 236 sites๐Ÿ“ Vienna๐Ÿ“ Ghent๐Ÿ“ Copenhagen Princess Maxima Center for Pediatric Oncology ยท Tests: Trametinib, Dexamethasone, Cyclophosphamide, Cytarabine, Intrathecal chemotherapy HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies NCT05751044Phase 1, Phase 233 sites๐Ÿ“ Vienna๐Ÿ“ Ghent๐Ÿ“ Copenhagen Princess Maxima Center for Pediatric Oncology ยท Tests: Dasatinib, Venetoclax, Dexamethasone, Cyclophosphamide, Cytarabine Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies NCT07648264Phase 360 sites๐Ÿ“ Orange๐Ÿ“ Denver๐Ÿ“ Coral Springs CSL Behring ยท Tests: IgPro20 UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 NCT05535855Phase 11 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19 Directed CAR T Cell A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) NCT06124157Phase 2161 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Tucson National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801n/a6 sites๐Ÿ“ Aurora๐Ÿ“ Atlanta๐Ÿ“ Cincinnati Children's Hospital Medical Center, Cincinnati ยท Tests: 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid)โ€ฆ Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR NCT03676504Phase 1, Phase 22 sites๐Ÿ“ Heidelberg๐Ÿ“ Heidelberg University Hospital Heidelberg ยท Tests: CD19.CAR T Cells, Fludarabine, Cyclophosphamide Study of Out of Specification for Tisagenlecleucel NCT04094311Phase 355 sites๐Ÿ“ Hamilton๐Ÿ“ Ottawa๐Ÿ“ Toronto Novartis Pharmaceuticals ยท Tests: CTL019 The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL NCT03509961Phase 224 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Duarte Pediatric Transplantation & Cellular Therapy Consortium ยท Tests: NGS-MRD, Myeloablative allogeneic HCT with a non-TBI conditioning regimen Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia NCT07040982Phase 11 site๐Ÿ“ Duarte City of Hope Medical Center ยท Tests: Asciminib, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL. NCT06250959Phase 21 site๐Ÿ“ Suzhou Chen Suning ยท Tests: Blinatumomab Injection [Blincyto], Doxorubicin Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974Phase 21 site๐Ÿ“ Minneapolis Masonic Cancer Center, University of Minnesota ยท Tests: HSCT with TBI Regimen, HSCT with Non-TBI Regimen MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717Phase 21 site๐Ÿ“ Minneapolis Masonic Cancer Center, University of Minnesota ยท Tests: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam Registry of Older Patients With Cancer NCT01137825n/a7 sites๐Ÿ“ Boone๐Ÿ“ Chapel Hill๐Ÿ“ Greenville UNC Lineberger Comprehensive Cancer Center A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia NCT07205315EARLY Phase 12 sites๐Ÿ“ Zhengzhou๐Ÿ“ Tianjin Grit Biotechnology ยท Tests: GT801 Injection CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol NCT05648019Phase 22 sites๐Ÿ“ Singapore๐Ÿ“ Singapore KK Women's and Children's Hospital ยท Tests: Anti-CD19 CAR T-cells Orphan Indications for CD19 Redirected Autologous T Cells NCT04276870Phase 21 site๐Ÿ“ Philadelphia Stephan Grupp MD PhD ยท Tests: Murine CART19 Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment NCT01087333n/a1 site๐Ÿ“ Bethesda National Cancer Institute (NCI) Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia NCT02877303Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy